Business & Finance

KV Pharmaceutical reports preliminary revenue of $108.8 million for Q2

Published in Medical Letter on the CDC and FDA, December 10th, 2006

KV Pharmaceutical Co. (KVa/KVb) reported preliminary financial results reflecting strong revenue growth for the second quarter and first 6 months of fiscal 2007, ended September 30, 2006. Revenues for the second quarter increased 13% to $108.8 million, compared to $96.3 million for the second quarter of fiscal 2006, with the company's Ther-Rx branded drug unit reporting revenue growth of 36%.

Gross profit for the second quarter increased to $69.4 million, up $7.1 million, or 11% over the prior year's quarter, due primarily to higher Ther-Rx sales which represented 42% of overall revenues versus 35% for the second quarter of fiscal 2006.

Net income...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2006-12-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry